This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Telix Pharmaceuticals has entered an agreement to add Subtle Medical’s AI software for enhancing prostate-specific membrane antigen (PSMA) PET prostate cancer scans to its product portfolio. SubtlePET is a U.S.
Telix Pharmaceuticals Ltd. announced the news on July 31, with the decision applying to its TLX250-CDx investigational agent for clear cell renal cell carcinoma (brand name Zircaix).
Eckert & Ziegler has entered into an agreement with Actinium Pharmaceuticals to supply the firm with the radioisotope actinium-225 (Ac-225). Actinium will continue developing its lead radiopharmaceutical product Actimab-A, as well as additional early and late-stage development candidates for both U.S. and international clinical trials.
Telix Pharmaceuticals recently submitted its license application to the FDA for the investigational positron emission tomography agent TLX250-CDx (Zircaix).
Telix Pharmaceuticals has entered into an asset purchase agreement with ImaginAb initially worth $45 million. Under terms of the deal, Telix will acquire a pipeline of therapeutic candidates such as DLL3 and integrin v6, a biologics technology platform, and a protein engineering and discovery research facility in California, it said.
Patient Care Solutions is one of GEHCs four individual segments, along with Imaging, Advanced Visualization Solutions, and Pharmaceutical Diagnostics. GE HealthCare (GEHC) has named Jeannette Bankes as president and CEO of its Patient Care Solutions segment, effective May 1, 2025.
Telix Pharmaceuticals is expanding its theranostic pipeline with newly acquired assets targeting fibroblast activation protein (FAP) in nuclear medicine.
Shuttle Pharmaceuticals Holdings has closed a previously announced underwritten public common stock offering, with aggregate gross proceeds of approximately $5.8 The Gaithersburg, MD-based specialty pharmaceutical company offered 19.1 million shares of its common stock at a public offering price of 30 per share.
milla1cf Tue, 01/23/2024 - 13:50 January 23, 2024 — Bayer announced Nelson Ambrogio as the new Head of the Radiology Business at its Pharmaceuticals Division, effective April 1, 2024. He will report to Stefan Oelrich , Member of the Board of Management, Bayer AG, and President Pharmaceuticals.
Fusion Pharmaceuticals announced a patent dispute settlement and new licensing agreement with Heidelberg University and Euratom for exclusive, worldwide rights to their existing patent for FPI-2265, an actinium-225-based targeted radiotherapy for the treatment of prostate-specific membrane antigen (PSMA)-expressing cancers.
Telix Pharmaceuticals said that the U.S. Through this NDA, Melbourne, Australia-based Telix plans to target underserved populations across the U.S. through its established nuclear pharmacy distribution partnerships and experience, the company said.
NorthStar Medical Radioisotopes is routinely manufacturing copper-67(Cu-67. Read more on AuntMinnie.com Related Reading: NorthStar appoints new president/CEO NorthStar installs accelerator at its new Wisc.
Telix Pharmaceuticals is highlighting that the first patient has been dosed with the company's TLX250-CDx (Zr-89 DFO-girentuximab) for clear cell renal cell carcinoma, the most common and aggressive form of kidney cancer. Telix is moving forward toward completing a Biologics License Application submission for TLX250-CDx with the U.S.
Originally started as an executive recruiting firm focused on the pharmaceutical industry, it quickly evolved into an IT recruiting firm with a strong focus on Cyber Security. He also worked in the telecom/Internet industry for McLeod USA, as well as a Pharmaceutical rep for Sepracor in Minneapolis, MN.
Australia-based Telix Pharmaceuticals has filed with the U.S. Securities and Exchange Commission (SEC) to list its ordinary shares and trade on the Nasdaq under the ticker symbol “TLX.” Telix is not proposing to raise capital or issue any new shares, it said. At the same time, Telix provided a third-quarter 2024 business update.
a therapeutic oncology company and 3B Pharmaceuticals (3BP) GmbH, a biotechnology company developing targeted radiopharmaceutical drugs and diagnostics for cancer detection and treatment, announced an exclusive licensing agreement for RefleXion to develop and commercialize a specific 3BP molecule to direct its SCINTIX biology-guided radiotherapy.
hospitals and pharmaceutical companies and that QP-Prostate was initially cleared in 2021 for automated segmentation of prostate regions. Food and Drug Administration (FDA) for the use of its QP-Prostate MRI software to help detect and diagnose prostate cancer.
Telix Pharmaceuticals has selected Cardinal Health to distribute its PET agent TLX250-CDx (Zircaix) for imaging kidney cancer in the U.S., subject to its regulatory approval.
GE HealthCare (GEHC) reported a 1% growth in existing operation revenues and an increase in profitability in its second quarter of 2024, citing solid performance in its Pharmaceutical Diagnostics segment. For the period (end-September 30), GEHC had total revenues of $4.86 billion, flat compared with $4.82 billion in the same period last year.
milla1cf Wed, 06/21/2023 - 19:47 June 21, 2023 — Fresenius Kabi , a leading provider of injectable medicines, announced today it has launched the diagnostic pharmaceutical agent, Sincalide for Injection, an authorized generic for Bracco Diagnostics Inc. ’s s Kinevac (Sincalide for Injection) product.
Carestream Health has secured a distribution contract for its radiology, cardiology, urology, endoscopy, and pharmaceutical offerings with BSF Medical - SARL of Bir El Djir, Algeria. BSF Medical - SARL is one of Algeria's largest medical equipment distributors in both public and private sectors, Carestream said.
Proscia’s user base is made up of over 10,000 pathologists and scientists, including those from 14 of the top 20 pharmaceutical companies and leading anatomic pathology laboratories. In modernizing its practice with Proscia, CellNetix will achieve greater flexibility along with productivity and efficiency gains in its routine workflows.
Telix Pharmaceuticals has completed the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for its new PET agent, TLX250-CDx. TLX250-CDx (Zircaix) characterizes renal masses as clear cell renal cell carcinoma, the company said.
In previous smaller studies , zirconium-89 (Zr-89) girentuximab (Zircaix, Telix Pharmaceuticals) PET/CT imaging differentiated ccRC tumors from other kidney tumor types based on its ability to bind to carbonic anhydrase 9 (CAIX), an antigen highly expressed by ccRCC cancer cells.
billion, which the company attributed to advanced visualization solutions (AVS) and pharmaceutical diagnostics, with overall strength in the U.S. billion, which the company attributed to advanced visualization solutions (AVS) and pharmaceutical diagnostics, with overall strength in the U.S. Revenue for the quarter came to $5.3
The 52,000-sq-ft facility will provide biopharmaceutical and pharmaceutical companies with development services and dose manufacturing capacity for key imaging and therapeutic radioisotopes, including actinium-225, lutetium-177, copper-64, copper-67, and indium-111, among others, the company said.
The end-to-end care continuum is designed to support clinicians and promote developments for lung health in the pharmaceutical and medical device industries. The end-to-end care continuum is designed to support clinicians and promote developments for lung health in the pharmaceutical and medical device industries.
Food and Drug Administration (FDA) has approved a new drug application (NDA) for Telix Pharmaceuticals' TLX007-CDx (Gozellix) for prostate cancer imaging. At the time of its NDA application, the Melbourne, Australia-based firm planned to target underserved populations across the U.S.
from Cardinal Health FDA clears Cardinal's Lymphoseek for pediatric use Cardinal Health joins SNMMI's Value Initiative Cardinal Health taps new head of pharmaceutical unit Cardinal Health Nuclear & Precision Health Solutions plans to showcase it. Read more on AuntMinnie.com Related Reading: Navidea secures $7.5M
Food and Drug Administration (FDA) has granted Clarity Pharmaceuticals fast-track designation for its copper-64 (Cu-64) sarcophagine (SAR) bisPSMA radiopharmaceutical.
Read more on AuntMinnie.com Related Reading: NorthStar manufactures Cu-67 for Clarity Pharmaceuticals NorthStar appoints new president/CEO NorthStar installs accelerator at its new Wisc. NorthStar Medical Isotopes will supply Bayer with the medical radioisotope actinium-22.
Telix Pharmaceuticals plans to spin off its wholly-owned subsidiary Rhine Pharma and structure it as an independent company. Rhine Pharma’s mission will be to expand global access to radiopharmaceuticals for cancer imaging and treatment using two generator-produced isotopes, technetium-99m (Tc-99m) and rhenium-188 (Re-188), the company said.
Melbourne, Australia-based Telix Pharmaceuticals reported a spike in revenue for the second quarter of 2024, citing strong sales of Illuccix (gallium-68 prostate-specific membrane antigen [PSMA]-11), its PSMA-PET radiotracer kit for prostate cancer imaging.
The company’s Pharmaceutical Diagnostics segment generated $639 million in second-quarter revenues, a 14% increase on an organic basis over last year, GE HealthCare reported. Pharmaceutical Diagnostics segment EBIT was $200 million, up 31% over last year. Segment EBIT was $178 million, down 7% from the second quarter of 2023.
Clarity Pharmaceuticals has secured fast-track designation from the U.S. Food and Drug Administration (FDA) for its copper-67 (Cu-67) SAR-bisPSMA radiopharmaceutical for treating advanced prostate cancer.
Telix Pharmaceuticals has submitted a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) for its PET radiotracer TLX101-CDx (Pixclara) for imaging brain cancer.
Coronary computed tomography angiography (CCTA) is cheaper, easier to use and its results are easier to understand than Intravascular ultrasound (IVUS), making it ideal for clinical trials of cardi
Bayer has appointed Nelson Ambrogio as its new head of radiology business in its pharmaceuticals division. Ambrogio will serve on Bayer's pharmaceuticals executive committee and be based in Berlin, Germany; he will report to Stefan Oelrich, who is a member of the company's board of management and president of its pharmaceuticals division.
The companies noted that the flexibility of the agreement makes it possible to respond to the needs of pharmaceutical partners at different stages of radiopharmaceutical development and commercialization while addressing regulatory requirements worldwide. AtomVie's new facility is set to open later this year in Hamilton, Ontario, Canada.
TerraPower Isotopes has shipped its first samples of Actinium-225 (Ac-225) to two pharmaceutical companies to develop targeted cancer treatments in drug trials. Ac-225 is an alpha-emitting radionuclide that can be attached to a ligand that binds to cancer cells.
Telix Pharmaceuticals has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for its clear cell renal cell carcinoma PET radiotracer TLX250-CDx (Zircaix). It has also requested priority review. In addition, Telix said it has opened an expanded access program in the U.S.
We organize all of the trending information in your field so you don't have to. Join 5,000 users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content